CD19 and diffuse large B-cell lymphoma: Tisagenlecleucel (Tisa-cel or Kymriah®), an autologous CD19-targeted CAR-T cell product, is FDA approved for treating patients with r/r DLBCL that fails at least two previous lines of systemic therapy [101].